# A Study of ICP-022 in Patients With R/R DLBCL

> **NCT04438005** · PHASE2 · COMPLETED · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 3 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** ICP-022

## Key facts

- **NCT ID:** NCT04438005
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-07
- **Primary completion:** 2021-11-05
- **Final completion:** 2021-12-13
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04438005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04438005, "A Study of ICP-022 in Patients With R/R DLBCL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04438005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*